← 返回

伴侵袭性临床特征的双表型 NK-大颗粒淋巴细胞白血病:病例报告及文献综述

英文原题:Biphenotypic NK-Large granular lymphocytic leukemia with aggressive clinical features: a case report and literature review.

查看英文原题

Biphenotypic NK-Large granular lymphocytic leukemia with aggressive clinical features: a case report and literature review.

PubMed 2025/07/23(内容时间) Ann Hematol Q3 · IF 2.3(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

自然杀伤大颗粒淋巴细胞白血病(NK-LGLL)是一种罕见的、通常呈惰性病程的淋巴增殖性疾病,以自然杀伤(NK)细胞的克隆性扩增为特征。

我们报告一例49岁男性患者,表现为四个月进行性乏力,最初归因于贫血,最终被诊断为具有侵袭性特征的非典型NK-LGLL表现,包括肝脾肿大、噬血细胞综合征和快速疾病进展。初期临床和形态学上与侵袭性NK细胞白血病(ANKL)的重叠使诊断复杂化。

然而,通过分子谱分析和Epstein-Barr病毒DNA检测,确诊为NK-LGLL,凸显了基因检测在解决诊断不确定性中的重要性。本报告还讨论了治疗挑战,因为目前NK-LGLL的治疗尚未标准化,且传统免疫抑制治疗存在感染风险。在本例中,PI3K抑制剂linperlisib治疗导致短暂缓解,提示其作为新型治疗方法的潜力。该药物后来因感染而停用,患者随后接受了以沙利度胺为基础的方案。末次随访时,患者临床稳定。本病例强调了NK细胞恶性肿瘤的诊断复杂性,并倡导将分子见解整合到诊断和治疗策略中。

进一步研究靶向治疗,包括通路特异性抑制剂,可能改善侵袭性NK-LGLL的管理。

展开英文摘要原文

Natural killer large granular lymphocytic leukemia (NK-LGLL) is a rare and typically indolent lymphoproliferative disorder characterized by clonal expansion of natural killer (NK) cells.

We report a case of a 49-year-old man presented with a four-month history of progressive fatigue that was, initially attributed to anemia who was diagnosed with an atypical manifestation of NK-LGLL with aggressive features including hepatosplenomegaly, hemophagocytic syndrome, and rapid disease progression. Initial clinical and morphological overlaps with aggressive NK-cell leukemia (ANKL) complicated the diagnosis.

However, through molecular profiling and Epstein-Barr virus DNA detection, NK-LGLL has been confirmed, underscoring the importance of genetic testing in resolving diagnostic uncertainties. The report also discusses the therapeutic challenges, as current treatments for NK-LGLL are not standardized, and conventional immunosuppressive therapies carry the risk of infections.

In the present case, treatment with the PI3K inhibitor linperlisib led to transient remission, suggesting its potential as a novel therapeutic approach. The drug was later discontinued due to infections, and the patient subsequently received a thalidomide-based regimen. At last follow-up, the patient remained clinically stable. This case emphasizes the diagnostic complexity of NK cell malignancies and advocates the integration of molecular insights into diagnostic and treatment strategies.

Further research into targeted therapies, including pathway-specific inhibitors, may enhance the management of aggressive NK-LGLL.

论文信息

作者
Liu B、Yu T、Zhou N、Yi S
第一作者单位
Department of Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, The Fourth Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, People's Republic of China.China
通讯作者单位
State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China. yishuhua@ihcams.ac.cn.China
文献类型
病例报告 · 综述
期刊
Annals of hematology2025 Aug
原文标识
PubMed 40699309 · DOI 10.1007/s00277-025-06492-x